Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, commonly causes gastrointestinal effects including nausea, diarrhea, and constipation
Los agonistas del receptor GLP-1 actan de varias maneras simultneas : estimulan la secrecin de insulina cuando los niveles de glucosa estn elevados, suprimen la liberacin de glucagn (hormona que aumenta el azcar en sangre), retrasan el vaciamiento gstrico y reducen el apetito actuando sobre centros del cerebro que regulan la saciedad
When B12 levels are insufficient, individuals may experience symptoms such as fatigue, irritability, poor concentration, and even physical issues like brittle nails and dull skin
10.1186/s12870-017-1179-z BMC Plant Biol
The present study was approved by The Institutional Animal Care and Use Committee of Renmin Hospital of Wuhan University
Pharmacol Res (2020) 152:104615